title: [Intravitreal implants: drug carriers and carriers of hope?].
abstract: Immunosuppressive agents are used for the therapy of noninfectious uveitis if intraocular quiescence and freedom from recurrences are not achievable with oral steroids at a low dosage. Partially, severe side effects are tolerated to preserve visual acuity even if the disease is limited to the eyes. Because of this a therapy would be desirable which is highly effective, limited to the eyes and with few side effects. For this fluocinolone acetonide and dexamethasone drug delivery systems were developed. Dexamethasone implants were already approved for the therapy of retinal vein occlusions and are used successfully. Diabetic macular edema would be another possible indication for dexamethasone implants.
authors.affiliation: Universitätsaugenklinik Charité, Virchow- Klinikum, Augustenburger Platz 1, 13353, Berlin, Deutschland. Sibylle.Winterhalter@charite.de
authors.forename: S
authors.initials: S
authors.lastname: Winterhalter
authors.forename: P
authors.initials: P
authors.lastname: Ruokonen
authors.forename: K H
authors.initials: KH
authors.lastname: van der Velden
authors.forename: U
authors.initials: U
authors.lastname: Pleyer
authors.forename: A M
authors.initials: AM
authors.lastname: Joussen
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects; D002908:Chronic Disease; D003907:Dexamethasone / Q000008:administration & dosage* / Q000009:adverse effects; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000276:immunology; D004337:Drug Carriers; D004343:Drug Implants; D004351:Drug Resistance; D005446:Fluocinolone Acetonide / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008269:Macular Edema / Q000188:drug therapy* / Q000276:immunology; D016032:Randomized Controlled Trials as Topic; D012170:Retinal Vein Occlusion / Q000188:drug therapy* / Q000276:immunology; D055502:Secondary Prevention; D015867:Uveitis, Intermediate / Q000188:drug therapy* / Q000276:immunology; D015866:Uveitis, Posterior / Q000188:drug therapy* / Q000276:immunology; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body / Q000187:drug effects*
chemical_list: D000305:Adrenal Cortex Hormones; D004337:Drug Carriers; D004343:Drug Implants; D007166:Immunosuppressive Agents; D005446:Fluocinolone Acetonide; D003907:Dexamethasone